Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

This study tests whether using befotertinib (a targeted EGFR-blocking drug) combined with bevacizumab or standard platinum-based chemotherapy before surgery can shrink tumors and improve surgical outcomes in people with early-to-mid stage non-small cell lung cancer (NSCLC) that has an EGFR mutation. **You may be eligible if...** - You are 18–75 years old with NSCLC confirmed to have an EGFR-sensitive mutation - Your cancer is at stage II–IIIA and has not spread to distant organs - You are eligible for and can tolerate curative surgery - You have not received any prior cancer treatment for NSCLC - You have good lung and organ function **You may NOT be eligible if...** - You have already received any systemic cancer treatment for your lung cancer - You have unstable medical conditions such as uncontrolled high blood pressure, active infection, or severe angina - Your cancer has spread to the brain or other distant sites Talk to your doctor to see if this trial is right for you.